智通财经APP讯,联邦制药(03933)公布,预期该集团于2025年取得溢利约20亿元,而2024年溢利约26.58亿元。溢利减少主要由于年内中间体产品及原料药的市场价格下跌,导致中间体产品及原料药的分部溢利与2024年比较,分别下降约16亿元及约4亿元。制剂产品分部溢利大幅上升约14亿元,其中来自诺和诺德股份有限公司的许可费收入贡献约13亿元,部分补偿了中间体产品及原料药分部的溢利下降。
智通财经APP讯,联邦制药(03933)公布,预期该集团于2025年取得溢利约20亿元,而2024年溢利约26.58亿元。溢利减少主要由于年内中间体产品及原料药的市场价格下跌,导致中间体产品及原料药的分部溢利与2024年比较,分别下降约16亿元及约4亿元。制剂产品分部溢利大幅上升约14亿元,其中来自诺和诺德股份有限公司的许可费收入贡献约13亿元,部分补偿了中间体产品及原料药分部的溢利下降。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.